Free Trial

Elekta AB (publ) (OTCMKTS:EKTAY) Sees Significant Decline in Short Interest

Elekta AB (publ) logo with Medical background

Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report) was the target of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 100 shares, a drop of 99.5% from the January 15th total of 19,700 shares. Based on an average daily volume of 16,900 shares, the days-to-cover ratio is presently 0.0 days.

Elekta AB (publ) Stock Up 2.2 %

OTCMKTS:EKTAY traded up $0.14 during trading hours on Friday, hitting $6.24. 5,054 shares of the company traded hands, compared to its average volume of 8,908. The company has a quick ratio of 0.81, a current ratio of 1.05 and a debt-to-equity ratio of 0.60. The firm's 50-day simple moving average is $5.69 and its 200-day simple moving average is $6.09. Elekta AB has a one year low of $5.25 and a one year high of $8.24. The company has a market cap of $2.39 billion, a PE ratio of 20.97 and a beta of 1.22.

Elekta AB (publ) (OTCMKTS:EKTAY - Get Free Report) last issued its quarterly earnings data on Wednesday, November 27th. The company reported $0.06 earnings per share for the quarter. Elekta AB (publ) had a return on equity of 11.07% and a net margin of 5.65%. Equities analysts predict that Elekta AB will post 0.36 earnings per share for the current year.

Elekta AB (publ) Cuts Dividend

The business also recently announced a dividend, which will be paid on Thursday, March 27th. Shareholders of record on Friday, March 7th will be issued a dividend of $0.1072 per share. The ex-dividend date is Friday, March 7th. Elekta AB (publ)'s payout ratio is presently 48.00%.

Analysts Set New Price Targets

Separately, Sanford C. Bernstein raised shares of Elekta AB (publ) from a "strong sell" rating to a "hold" rating in a research report on Wednesday, January 29th.

Check Out Our Latest Analysis on Elekta AB (publ)

About Elekta AB (publ)

(Get Free Report)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.

Featured Articles

Should You Invest $1,000 in Elekta AB (publ) Right Now?

Before you consider Elekta AB (publ), you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elekta AB (publ) wasn't on the list.

While Elekta AB (publ) currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines